Note: This is a 31 site clinical trial for people who were non-responders to certain types of hepatitis C medications. Alan
The study will enroll well-compensated cirrhotic as well as non-cirrhotic subjects treatment experienced with an NS5a Inhibitor + sofosbuvir and will include patients who did not complete the prescribed duration due to adverse event or any reason other than for non/poor compliance. Subjects will be randomized to 12 or 16 weeks of treatment.
To learn more about this study, click here
To visit our Clinical Trial Reference Guide, click here
Share This Page